News
AXDX
1.300
+5.69%
0.070
Weekly Report: what happened at AXDX last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at AXDX last week (0708-0712)?
Weekly Report · 07/15 10:22
Weekly Report: what happened at AXDX last week (0701-0705)?
Weekly Report · 07/08 10:23
Weekly Report: what happened at AXDX last week (0624-0628)?
Weekly Report · 07/01 10:23
Weekly Report: what happened at AXDX last week (0617-0621)?
Weekly Report · 06/24 10:28
Weekly Report: what happened at AXDX last week (0610-0614)?
Weekly Report · 06/17 10:22
Weekly Report: what happened at AXDX last week (0603-0607)?
Weekly Report · 06/10 10:24
ACCELERATE DIAGNOSTICS - RECEIVED WRITTEN NOTICE FROM NASDAQ NOTIFYING CO THAT IT HAD REGAINED COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT
Reuters · 06/05 21:18
Weekly Report: what happened at AXDX last week (0527-0531)?
Weekly Report · 06/03 10:26
Accelerate Diagnostics Unveils Executive Incentive Plan Linked to FDA Goals
TipRanks · 05/30 21:20
Weekly Report: what happened at AXDX last week (0520-0524)?
Weekly Report · 05/27 10:28
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 05/23 20:31
12 Health Care Stocks Moving In Tuesday's Intraday Session
Biodexa Pharmaceuticals (NASDAQ:BDRX) stock increased by to $ during Tuesday's regular session. The company's market cap stands at $ million. As per the news, the Q1 earnings report came out 4 days ago. Losers Dare Bioscience and American Oncology Network.
Benzinga · 05/21 16:31
Weekly Report: what happened at AXDX last week (0513-0517)?
Weekly Report · 05/20 10:25
Accelerate Diagnostics’ Shareholder Decisions at Annual Meeting
TipRanks · 05/13 20:23
Accelerate Diagnostics, Inc. Q1 2024 Financial Report: Condensed Consolidated Balance Sheets and Management's Discussion and Analysis of Financial Condition and Results of Operations
Press release · 05/13 12:17
Weekly Report: what happened at AXDX last week (0506-0510)?
Weekly Report · 05/13 10:30
CORRECTED-(OFFICIAL)- BRIEF-Accelerate Diagnostics Q1 Sales USD 2.9 Million (May 8)
Reuters · 05/10 21:46
AXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q1 2024
Accelerate Diagnostics reported earnings per share of -88 cents for the first quarter of 2024. The company reported revenue of $2.92 million. This was 2.63% worse than the analyst estimate for revenue in the same period. Accelerate Diagnostic reported results for the second quarter of 2016.
Investorplace · 05/09 01:57
Accelerate Diagnostics GAAP EPS of -$0.88 misses by $0.16, revenue of $2.9M misses by $0.1M
Seeking Alpha · 05/08 20:51
More
Webull provides a variety of real-time AXDX stock news. You can receive the latest news about Accelerate Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About AXDX
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.